Dexrabeprazole sodium (DEX), 2-{[4-(3-methoxy propoxy)-3-methylpyridin-2-yl]methyl sulfinyl}-1H-benzimidazole is a proton pump inhibitor. The drug is commercially available as tablets for oral administration. In the present work, two rapid, economical and accurate methods have been developed for the estimation of Dexrabeprazole sodium (DEX) in tablet dosage form. Method A is first order derivative spectroscopy where derivative amplitudes were calculated by considering one minima and one maxima

more »

... f the curve. Method B is area under the curve in which wavelength range 278-303nm was selected. Linearity was observed in the concentration range 6-36 µg/ml for both the methods (r 2 =0.9994 for method A and r 2 =0.9991for method B). The % assay for the marketed formulation by first order derivative and area under the curve was found to be 99.75 % and 100.03% respectively. The method was validated with respect to linearity, precision and accuracy studies. Recovery studies for first order derivative spectroscopy and area under the curve was found to be in the range of 100.08%-102.08% and 98.25%-100.75% respectively. Both the methods were found to be simple, precise and accurate and can be employed for routine quality control analysis of dexrabeprazole sodium in bulk as well as from its dosage form. Keywords: Area under the curve, Dexrabeprazole sodium, First order derivative spectroscopy and UV spectrophotometery. M. N. Dole * et al.